Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

Recruiting now · Early Phase 1

Conditions studied: X-Linked Retinitis Pigmentosa

In brief

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

Key facts

Study ID

NCT05874310

Run by

Frontera Therapeutics

People needed

18

Starts

2023-02-01

Expected to finish

2027-11-01

Last updated by the study team

2023-05-24

Who can join

Age: 8 and older, up to 45. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the Informed Consent Form; 4.Subjects who are confirmed with variants of RPGR ;

You may not qualify if…

• Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.

Where it is running

• Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (enrolling)
• Eye & ENT hospital of Fudan university — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.